Cargando…

Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery

Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of failure in the respec...

Descripción completa

Detalles Bibliográficos
Autores principales: Botelho, Hugo M., Uliyakina, Inna, Awatade, Nikhil T., Proença, Maria C., Tischer, Christian, Sirianant, Lalida, Kunzelmann, Karl, Pepperkok, Rainer, Amaral, Margarida D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356983/
https://www.ncbi.nlm.nih.gov/pubmed/25762484
http://dx.doi.org/10.1038/srep09038
_version_ 1782361070128594944
author Botelho, Hugo M.
Uliyakina, Inna
Awatade, Nikhil T.
Proença, Maria C.
Tischer, Christian
Sirianant, Lalida
Kunzelmann, Karl
Pepperkok, Rainer
Amaral, Margarida D.
author_facet Botelho, Hugo M.
Uliyakina, Inna
Awatade, Nikhil T.
Proença, Maria C.
Tischer, Christian
Sirianant, Lalida
Kunzelmann, Karl
Pepperkok, Rainer
Amaral, Margarida D.
author_sort Botelho, Hugo M.
collection PubMed
description Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of failure in the respective protein to reach the plasma membrane. However, specific therapies for these diseases are remarkably lacking. Herein, we report a robust platform for drug discovery applied to a paradigmatic genetic disorder affecting intracellular trafficking – Cystic Fibrosis. This platform includes (i) two original respiratory epithelial cellular models incorporating an inducible double-tagged traffic reporter; (ii) a plasma membrane protein traffic assay for high-throughput microscopy screening; and (iii) open-source image analysis software to quantify plasma membrane protein traffic. By allowing direct scoring of compounds rescuing the basic traffic defect, this platform enables an effective drug development pipeline, which can be promptly adapted to any traffic disorder-associated protein and leverage therapy development efforts.
format Online
Article
Text
id pubmed-4356983
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-43569832015-03-17 Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery Botelho, Hugo M. Uliyakina, Inna Awatade, Nikhil T. Proença, Maria C. Tischer, Christian Sirianant, Lalida Kunzelmann, Karl Pepperkok, Rainer Amaral, Margarida D. Sci Rep Article Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of failure in the respective protein to reach the plasma membrane. However, specific therapies for these diseases are remarkably lacking. Herein, we report a robust platform for drug discovery applied to a paradigmatic genetic disorder affecting intracellular trafficking – Cystic Fibrosis. This platform includes (i) two original respiratory epithelial cellular models incorporating an inducible double-tagged traffic reporter; (ii) a plasma membrane protein traffic assay for high-throughput microscopy screening; and (iii) open-source image analysis software to quantify plasma membrane protein traffic. By allowing direct scoring of compounds rescuing the basic traffic defect, this platform enables an effective drug development pipeline, which can be promptly adapted to any traffic disorder-associated protein and leverage therapy development efforts. Nature Publishing Group 2015-03-12 /pmc/articles/PMC4356983/ /pubmed/25762484 http://dx.doi.org/10.1038/srep09038 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Botelho, Hugo M.
Uliyakina, Inna
Awatade, Nikhil T.
Proença, Maria C.
Tischer, Christian
Sirianant, Lalida
Kunzelmann, Karl
Pepperkok, Rainer
Amaral, Margarida D.
Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery
title Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery
title_full Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery
title_fullStr Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery
title_full_unstemmed Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery
title_short Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery
title_sort protein traffic disorders: an effective high-throughput fluorescence microscopy pipeline for drug discovery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356983/
https://www.ncbi.nlm.nih.gov/pubmed/25762484
http://dx.doi.org/10.1038/srep09038
work_keys_str_mv AT botelhohugom proteintrafficdisordersaneffectivehighthroughputfluorescencemicroscopypipelinefordrugdiscovery
AT uliyakinainna proteintrafficdisordersaneffectivehighthroughputfluorescencemicroscopypipelinefordrugdiscovery
AT awatadenikhilt proteintrafficdisordersaneffectivehighthroughputfluorescencemicroscopypipelinefordrugdiscovery
AT proencamariac proteintrafficdisordersaneffectivehighthroughputfluorescencemicroscopypipelinefordrugdiscovery
AT tischerchristian proteintrafficdisordersaneffectivehighthroughputfluorescencemicroscopypipelinefordrugdiscovery
AT sirianantlalida proteintrafficdisordersaneffectivehighthroughputfluorescencemicroscopypipelinefordrugdiscovery
AT kunzelmannkarl proteintrafficdisordersaneffectivehighthroughputfluorescencemicroscopypipelinefordrugdiscovery
AT pepperkokrainer proteintrafficdisordersaneffectivehighthroughputfluorescencemicroscopypipelinefordrugdiscovery
AT amaralmargaridad proteintrafficdisordersaneffectivehighthroughputfluorescencemicroscopypipelinefordrugdiscovery